Biotechnology

Erasca

Erasca Showcases Cancer Drug Pipeline, ERAS-0015 Clinical Data Promising with Financial Stability to 2028

Erasca Presents Early Clinical Data for ERAS-0015, NSCLC Response Rate 62%-75%

Erasca released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6027 (forecast USD -0.2115)

Erasca Reports Q1 Net Loss and Operating Profit

Erasca Announces Positive Phase 1 Clinical Trial Results for RAS Drug ERAS-0015

Erasca Schedules Conference Call to Discuss Preliminary Dose Escalation Results for ERAS-0015

Erasca Updates Data Release Timeline for ERAS-0015

Erasca Completes HERKULES-3 Trial

Erasca released FY2025 Q4 earnings on March 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1024 (forecast USD -0.1067)

Erasca released FY2025 Annual Earnings on March 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4392 (forecast USD -0.4441)

Erasca Inc. Released Corporate Presentation on R&D Pipeline and Financing Status

Erasca Extends ERAS-0015 License in China

Erasca Inc. Secures Patent for Full KRAS Inhibitor ERAS-4001

Erasca Executives Discuss Clinical Data and R&D Pipeline of ERAS-0015

Erasca Inc. CFO and CBO David M. Chacko Buys Company's Common Stock

Erasca (ERAS) Files for a $150 Million IPO and Offers Over-Allotment Option to Underwriters

Erasca Reports Total Cash and Equivalents of Approximately $341.8 Million

HC Wainwright Upgrades Erasca's 2027 Fiscal Year Profit Forecast and Maintains Buy Rating

HC Wainwright Raises Erasca's Target Price to $11

Erasca Announces Cancer Elimination Strategy, Focusing on RAS/MAPK Pathway

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ERAS

LABU

SBIO

ARKG

Erasca (NASDAQ:ERAS) executives presented promising early clinical data for ERAS-0015, a RAS-targeting drug, at a Bank of America conference. They reported response rates of 62%-75% in non-small cell lung cancer and discussed plans for FDA discussions on accelerated approval. The company is also exploring combination therapies with pembrolizumab and has seen a 41% response rate in pancreatic cancer. Erasca received a patent for ERAS-0015, extending protection to 2043.

Market Beat

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

iShares Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

VG Health

Ark Genomic Revolution ETF

Bank of America

Merck

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference

J.P. Morgan analyst Anupam Rama has maintained a Buy rating on Erasca (ERAS) with a price target of $23.00, while the stock closed at $10.46. Rama has an average return of 23.7% and a success rate of 52.03% on his recommendations. Mizuho Securities also issued a Buy rating for Erasca, but Bank of America Securities reiterated a Sell rating on the same day.

Tip Ranks

iShares Global Healthcare

JPMorgan Chase

Sarepta Therap

Travere Therapeutics

Mizuho Financial

Mizuho Financial Group, Inc.

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)

Earnings Watch

Erasca | 10-Q: FY2026 Q1 Revenue: USD 0

Erasca | 8-K: FY2026 Q1 Revenue: USD 0

MRNA

SNDA

Healthcare stocks declined late Monday, with the NYSE Healthcare Index down 0.3% and the State Street Healthcare Select Sector SPDR ETF down 0.4%. Zoetis shares fell 7.5% after a price target cut by BNP Paribas. Moderna shares dropped 3.7% amid news of early-stage vaccine development. Sonida Senior Living reported a Q1 loss of $2.39 per share, leading to a 3.3% decline in shares. In contrast, Erasca shares rose 3% following a collaboration with Merck for a clinical trial.

Fidelity

Moderna

Zoetis

Sonida Senior Living

BNP Paribas

Factset Research

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks showed mixed performance on May 11, 2026, with the NYSE Healthcare Index up 0.2%. Moderna's shares fell 2.2% as it works on early-stage hantavirus vaccines. Sonida Senior Living reported a Q1 loss of $2.39 per share, leading to a 3.6% drop in its stock. In contrast, Erasca's shares rose 3.3% after announcing a collaboration with Merck for a clinical trial, while Merck's stock increased by 1.2%.

Fidelity MSCI Health Care Index

Direxion Healthcare Bull 3X

SPDR S&P Health Equip

SPDR S&P Health

Invesco Nasdaq Biotechnology ETF

iShares US Medical Devices

Sector Update: Healthcare Stocks Mixed in Afternoon Trading

Erasca (ERAS) has released preliminary Phase 1 data for its candidate ERAS 0015, alongside legal scrutiny regarding patent claims. The stock has seen a 36.33% decline over the past 30 days, despite a year-to-date return of 203.62%. Currently valued at approximately $3.1 billion, Erasca trades at a high price-to-book ratio of 10.4x, significantly above industry averages, indicating potential overvaluation. Investors are advised to consider the risks associated with clinical data and legal issues before making investment decisions.

Simplywall

Assessing Erasca (ERAS) Valuation After ERAS 0015 Data And Patent Investigation News

Erasca(ERAS.US)